Levobupivacaine hydrochloride (Synonyms: (S)-(-)-Bupivacaine monohydrochloride)

Name: Levobupivacaine hydrochloride
Brand: MedChemExpress
SKU: HY-B0653A
Rating: 5.0 (2 reviews)

Cat. No.: HY-B0653A Purity: 99.98%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer.

For research use only. We do not sell to patients.

Levobupivacaine hydrochloride Chemical Structure

CAS No. : 27262-48-2

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 66	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 66	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 38	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 60	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 84	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 108	In-stock	Estimated Time of Arrival: December 31
200 mg	USD 144	In-stock	Estimated Time of Arrival: December 31
500 mg	USD 228	In-stock	Estimated Time of Arrival: December 31
1 g		Get quote
5 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of Levobupivacaine hydrochloride:

Levobupivacaine Get quote

2 Publications Citing Use of MCE Levobupivacaine hydrochloride

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Sodium Channel Isoform Specific Products:

View All Isoforms

Na_v1.1 Na_v1.2 Na_v1.3 Na_v1.4 Na_v1.5 Na_v1.6 Na_v1.7 Na_v1.8

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Sodium channels, Ferroptosis^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	13 μM Compound: Levo-(S)-bupivacaine	Inhibition of wild-type human ERG channel expressed in CHO cells by whole-cell patch clamp technique Inhibition of wild-type human ERG channel expressed in CHO cells by whole-cell patch clamp technique	[PMID: 21624711]
CHO	IC₅₀	83 μM Compound: Levo-(S)-bupivacaine	Inhibition of human ERG Y652A mutant channel expressed in CHO cells by whole-cell patch clamp technique Inhibition of human ERG Y652A mutant channel expressed in CHO cells by whole-cell patch clamp technique	[PMID: 21624711]
HEK293	IC₅₀	1013 μM Compound: Levo-(S)-bupivacaine	Inhibition of human ERG F656A mutant channel expressed in HEK293 cells assessed as blockade of potassium tail current by whole-cell patch clamp technique Inhibition of human ERG F656A mutant channel expressed in HEK293 cells assessed as blockade of potassium tail current by whole-cell patch clamp technique	[PMID: 21624711]
HEK293	IC₅₀	13 μM Compound: Levo-(S)-bupivacaine	Inhibition of wild-type human ERG channel expressed in HEK293 cells assessed as blockade of potassium tail current by whole-cell patch clamp technique Inhibition of wild-type human ERG channel expressed in HEK293 cells assessed as blockade of potassium tail current by whole-cell patch clamp technique	[PMID: 21624711]
HEK293	IC₅₀	278 μM Compound: Levo-(S)-bupivacaine	Inhibition of human ERG Y652A mutant channel expressed in HEK293 cells assessed as blockade of potassium tail current by whole-cell patch clamp technique Inhibition of human ERG Y652A mutant channel expressed in HEK293 cells assessed as blockade of potassium tail current by whole-cell patch clamp technique	[PMID: 21624711]

In Vitro

Levobupivacaine (0-4 mM; 24 h) does not affect the viability of GES-1 cells but inhibits the viability of HGC27 and SGC7901 cells^[2].
Levobupivacaine (2 mM; 24, 48 or 72 h) enhances Erastin-induced inhibitory impact on HGC27 and SGC7901 cell viabilities; induces the levels of Fe²⁺, iron, and lipid ROS^[2].
Levobupivacaine (2 mM; 24 h) enhances the expression of miR-489-3p in HGC27 and SGC7901 cells, increases the levels of Fe²⁺ and iron^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	GES-1, HGC27 and SGC790
Concentration:	0, 0.5, 1, 2 and 4 mM
Incubation Time:	24 h
Result:	Did not affect the viability of normal gastric epithelial GES-1 cell lines but inhibited the viability of HGC27 and SGC7901 cells in a dose-dependent manner.

Cell Viability Assay^[2]

Cell Line:	HGC27 and SGC7901 (incubated with 5 μM erastin)
Concentration:	2 mM
Incubation Time:	24, 48 or 72 h
Result:	Enhanced erastin-induced inhibitory impact on HGC27 and SGC7901 cell viabilities; induced the levels of Fe²⁺, iron, and lipid ROS.

RT-PCR^[2]

Cell Line:	HGC27 and SGC7901 (incubated with 5 μM erastin)
Concentration:	2 mM
Incubation Time:	24 h
Result:	Enhanced the expression of miR-489-3p in HGC27 and SGC7901 cells, increased the levels of Fe²⁺ and iron.

In Vivo

Levobupivacaine (40 μmol/kg; IP; once daily for 25 days) significantly inhibits SGC7901 cell growth, and enhances the lipid ROS accumulation^[2].
Levobupivacaine (5 or 36 mg/kg; IP; single dosage) increases the latency to partial seizures and prevents the occurrence of generalized seizures at low dosage; reduces the latency to N-methyl-d-aspartate (NMDA)-induced seizures and increased seizure severity at high dosage^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CD1 mice (30-35 g; induced epileptic seizures by injecting with NMDA)^[3]
Dosage:	5 or 36 mg/kg
Administration:	IP; single dosage
Result:	Increased the latency to partial seizures and prevented the occurrence of generalized seizures at 5 mg/kg; reduced the latency to NMDA-induced seizures and increased seizure severity at 36 mg/kg.

Animal Model:	SCID nude mice (6-8 weeks; subcutaneously injected with 5×10⁶ SGC7901 cells)^[2]
Dosage:	40 μmol/kg
Administration:	IP; once daily for 25 days
Result:	Significantly inhibited SGC7901 cell growth, and enhanced the lipid ROS accumulation.

Clinical Trial

Molecular Weight

324.89

Formula

C₁₈H₂₉ClN₂O

CAS No.

27262-48-2

Appearance

Solid

Color

White to off-white

SMILES

O=C([C@H]1N(CCCC)CCCC1)NC2=C(C)C=CC=C2C.[H]Cl

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (307.80 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : ≥ 50 mg/mL (153.90 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.0780 mL	15.3898 mL	30.7796 mL
5 mM	0.6156 mL	3.0780 mL	6.1559 mL
10 mM	0.3078 mL	1.5390 mL	3.0780 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3 mg/mL (9.23 mM); Clear solution

This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 3 mg/mL (9.23 mM); Clear solution

This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.98%

Select Batch:

Data Sheet (280 KB) SDS (393 KB)

COA (251 KB) HNMR (144 KB) LCMS (85 KB)

Handling Instructions (2659 KB)

References

[1]. Sanford M, et al. Levobupivacaine: a review of its use in regional anaesthesia and pain management. Drugs. 2010 Apr 16;70(6):761-91. [Content Brief]

[2]. Mao SH, et al. Levobupivacaine Induces Ferroptosis by miR-489-3p/SLC7A11 Signaling in Gastric Cancer. Front Pharmacol. 2021 Jun 9;12:681338. [Content Brief]

[3]. Marganella C, et al. Comparative effects of levobupivacaine and racemic bupivacaine on excitotoxic neuronal death in culture and N-methyl-D-aspartate-induced seizures in mice. Eur J Pharmacol. 2005 Aug 22;518(2-3):111-5. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	3.0780 mL	15.3898 mL	30.7796 mL	76.9491 mL
	5 mM	0.6156 mL	3.0780 mL	6.1559 mL	15.3898 mL
	10 mM	0.3078 mL	1.5390 mL	3.0780 mL	7.6949 mL
	15 mM	0.2052 mL	1.0260 mL	2.0520 mL	5.1299 mL
	20 mM	0.1539 mL	0.7695 mL	1.5390 mL	3.8475 mL
	25 mM	0.1231 mL	0.6156 mL	1.2312 mL	3.0780 mL
	30 mM	0.1026 mL	0.5130 mL	1.0260 mL	2.5650 mL
	40 mM	0.0769 mL	0.3847 mL	0.7695 mL	1.9237 mL
	50 mM	0.0616 mL	0.3078 mL	0.6156 mL	1.5390 mL
	60 mM	0.0513 mL	0.2565 mL	0.5130 mL	1.2825 mL
	80 mM	0.0385 mL	0.1924 mL	0.3847 mL	0.9619 mL
	100 mM	0.0308 mL	0.1539 mL	0.3078 mL	0.7695 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Levobupivacaine hydrochloride Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Levobupivacaine27262-48-2(S)-(-)-Bupivacaine monohydrochlorideSodium ChannelFerroptosisNa channelsNa+ channelsanaestheticanalgesiccardiac toxicityCNS toxicityCYP450gastric cancerErastinNMDAInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Levobupivacaine hydrochloride (Synonyms: (S)-(-)-Bupivacaine monohydrochloride)

Customer Review

Other Forms of Levobupivacaine hydrochloride:

Levobupivacaine hydrochloride Related Antibodies

2 Publications Citing Use of MCE Levobupivacaine hydrochloride

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Sodium Channel Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Levobupivacaine hydrochloride Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Levobupivacaine hydrochloride Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report